BioNTech is a German biotechnology company known for its innovative research and development in the fields of immunotherapy, particularly in the development of mRNA-based vaccines. Founded in 2008, BioNTech initially focused on developing personalized cancer therapies, leveraging the body’s immune system to target and destroy tumor cells. The company gained global prominence for its role in developing one of the first COVID-19 vaccines against the SARS-CoV-2 virus, in collaboration with Pfizer, using messenger RNA (mRNA) technology to elicit an immune response. BioNTech continues to explore new therapeutic areas, including antiviral vaccines and tumor treatments, with the goal of advancing personalized medicine and improving patient outcomes.
BioNTech shifts focus from COVID-19 vaccines to pioneering cancer therapies, leveraging mRNA technology. Despite declining earnings, quarterly profits exceeded market expectations, with €1.08 per share and €1.19 billion in revenue.…